Unlike most tumor suppressor genes, missense mutations in the critical DNA binding domain (exons 4 to 8) are the most common variants in TP53, which are associated with the lower disease control rate and poorer survival outcomes with TKI treatment in contrast to TP53 wildtypes in EGFR-mutant NSCLC16,46. The gene discussed is TP53; the disease is neoplasm.